MSI Methylation Sciences, Inc.   Report issue

For profit Phase 2
Founded: Burnaby BC Canada (2007)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2013
NCT04623034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

MSI Methylation Sciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

s-adenosyl methionine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1